Inveready leads a €12 million round in Nanoligent to advance the development of its cancer nanodrug

- The round was led by Inveready and included participation from CDTI (through the Innvierte program), Clave Capital, and existing shareholders such as i&i Biotech Fund I, NanoIinvest, and AVANTECA Partners.
- The funds will enable the company to complete the regulatory preclinical development of its lead candidate, NNL-1524, and initiate its first clinical trial in patients with solid tumors.
- NNL-1524 is a cytotoxic nanoparticle targeting CXCR4, a key driver of tumor proliferation and metastasis.

Barcelona, 6 October 2025.

Nanoligent, a biotechnology company specialized in the development of targeted nanodrugs for cancer treatment, has closed a €12 million funding round. The round was led by Inveready, through its Inveready Biotech IV fund, with additional participation from CDTI (via the Innvierte program), Clave Capital, through its Clave Innohealth fund, and current investors i&i Biotech Fund I, Italian Angels for Growth, and Avanteca.

This capital injection will allow Nanoligent to complete the regulatory preclinical development of its lead compound, NNL1524, and advance into the clinic with a Phase Ia study in patients with solid tumors. The funding will also support manufacturing scale-up and optimization of production processes.

The company is led by Montserrat Cano, CEO, and Manuel Rodríguez, Chairman of the Board, both with a strong track record in drug development and management of biotech projects and companies.

Founded in 2017 as a spin-off of the Universitat Autònoma de Barcelona (UAB) and the Institut de Recerca at Hospital de la Santa Creu i Sant Pau, Nanoligent's technology is based on advanced protein engineering and nanobiotechnology to develop highly selective, multivalent cytotoxic nanoparticles targeting specific tumor markers.

Its lead candidate, NNL1524, targets CXCR4, a membrane receptor involved in tumorigenesis, cell proliferation, and metastasis, which is overexpressed in various hematological malignancies and solid tumors such as colorectal cancer, lung carcinoma, and breast cancer. In animal models, NNL1524 has demonstrated strong efficacy, achieving significant tumor regression as a monotherapy, with a favorable safety profile. These results reinforce its potential as a new therapeutic option in areas where significant unmet clinical needs remain.

Montserrat Cano, CEO of Nanoligent, commented: “This is a very important moment for Nanoligent. We feel deeply grateful for the significant recognition it represents, both at the national level with the incorporation of the new investors, and through the continued trust of our international investors. Their knowledge of the sector will be of great value in achieving the company’s upcoming milestones. Our team is fully prepared and committed to enthusiastically embracing the challenges of this new stage and to bringing our technology to where it truly matters: the patients who need it.”

“We strongly believe in the potential of Nanoligent’s nanodrugs to overcome the limitations of conventional cytotoxic conjugate therapies. Their low molecular weight, high cellular internalization capacity, and strong selectivity for the therapeutic target provide advantages. We are pleased to lead this round alongside a strong syndicate of specialized national and international investors,” said **Antonio Herce**, **Director at Inveready**.

The transaction was advised by Hoffmann Eitle and VentureTech Audit.

About Nanoligent

Nanoligent fue cofundada en 2017 por su presidente Manuel Rodríguez Mariscal, como spin-off fruto de más de 10 años de fructífera colaboración entre el grupo de Nanobiotecnología del Instituto de Biotecnología y Biomedicina de la Universidad Autónoma de Barcelona , co-dirigido por el catedrático Antonio Villaverde y la investigadora principal Esther Vázquez, y el Grupo de Oncogénesis y Fármacos Antitumorales del Instituto de Investigación Biomédica Sant Pau del Hospital de la Santa Creu i Sant Pau, encabezados por el catedrático Ramon Mangues, los tres también cofundadores de la empresa. Montserrat Cano se incorporó a la empresa en 2020, con más de 15 años de experiencia en empresas farmacéuticas y biotecnológicas. El objetivo de la empresa es desarrollar una plataforma tecnológica pionera basada en nanoconjugados de proteínas y fármacos dirigida a las fases metastáticas de distintos tipos de tumores.

About Inveready

Inveready is a leading financial services firm specialized in Alternative Assets, Wealth Management, and Investment Funds. Founded in 2008 as a venture capital fund, Inveready has evolved into one of the most active investment firms for small and medium-sized enterprises in Spain, currently managing over €2.4 billion.

The financial group organizes its services into three main business lines: Alternative Assets, which includes various direct investment strategies (Venture Capital, Life Sciences Venture Debt, Strategic Public Equity, Private Equity, and Infrastructure); Wealth Management, which advises clients across a range of high-value products and services; and Investment Funds, investing in small-cap equities with a value investing approach through its management company True Value.

With a team of 60 employees, Inveready is headquartered in San Sebastián, with offices in Barcelona and Madrid. The firm has been recognized as “Best Venture Capital Firm” by SpainCap in 2017 and “Best European Venture Debt Fund” by Preqin in 2023, among other awards.